Swedish Kancera making progress with ROR-inhibitor.
Do you have an opinion on Kancera? I heard of them before and have them on my watch list given they seem to be involved in novel projects, very obscure/off-the-radar, and tiny valuation. They also are working on HDAC6 and claim, at least in pre-clinic, that they have a more potent and more tolerable HDAC6 than Acetylon (CELG paid a good chunk for them earlier I believe).
One of the big risks I see is they only had ~31M SEK, or about $4.5M, as of 6/30/14. It would seem that they are going to need to raise money soon. Also, do you know how many shares are outstanding? I'd like to get a sense of fully-diluted market cap.
News 
Market Data 
Discover 
